chemieunternehmen.com

Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-university-to-collaborate-on-development-of-new-class-of-antibacterials-5137

Revenues without milestones increased in the first quarter of 2013 by 5% compared to the first quarter of 2012- Q1 2013 revenues amounted to EUR 17.1 m (2012: EUR 20.1 m); up 5% compared to Q1 2012 revenues of EUR 16.2 m on a … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-q1-2013-driving-innovation-efficiency-5135

The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/dana-farbers-belfer-institute-for-applied-cancer-science-and-evotec-establish-collaboration-in-oncology-5131

Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-compound-management-capability-to-east-coast-of-the-united-states-5129

Evotec AG today announced an auspicious step in research from Harvard University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/new-hormone-to-treat-diabetes-published-in-cell-5127

Evotec AG today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group, for three additional years. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-extends-drug-discovery-alliance-with-genentech-5125

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/forward-step-by-step-with-action-plan-2016—continued-revenue-growth—significant-pipeline-progress-5123

Evotec AG today announced that Dr Werner Lanthaler, Chief Executive Officer of Evotec, will resume his role as Chief Executive Officer of the Company with immediate effect after a period of leave due to health reasons. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/corporate-update-5119

Evotec AG today announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd-5117